NCT06339138View on ClinicalTrials.gov

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Active, not recruitingOBSERVATIONAL
Enrollment

589

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Chromophobe Renal Cell CarcinomaClear Cell Papillary Renal TumorClear Cell Renal Cell CarcinomaKidney OncocytomaPapillary Renal Cell CarcinomaUrothelial Carcinoma
Interventions
OTHER

Non-Interventional Study

Non-interventional study

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06339138 - Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | Biotech Hunter | Biotech Hunter